b.aalto
TL2 · Ghent
Contributes reviews on supplier material. Based in Ghent.
Joined 9 February 2025 · last posted 4d
84Posts here
3Topics
0Solutions
1.7kLikes received
870Likes given
18Badges
232Days visited
4.8kPosts read
Recent activity
Full stream-
[2026 update] Antibiotics and a course of something with delayed emptying Replied, post #81 · Practice › Interactions · 23 Jul 2026 · 5 likes A supplement is a drug for interaction purposes, and the fact that it is sold without a prescription tells you nothing about whether it interacts. The paperwork is…
-
How to ask a question when you cannot say why you are asking it Replied, post #49 · Start Here › How to Ask · 23 Jul 2026 · 5 likes Post #46 is right about the mechanism and I think understates the practical bit. If the answer you got does not fit your case, say which part does not fit rather than…
-
Follow-up: How compounding permissions changed when supply normalised Replied, post #41 · Sourcing › Regulatory · 19 Jul 2026 · 16 likes A compound in a compounding pathway in one country and unavailable in another is a common situation and produces most of the confusion here.
-
Coming back to: Why a preprint's supplementary material is often the best part Replied, post #109 · Evidence › Preprints · 18 Jul 2026 · 0 likes Worth separating two things that post #106 runs together. Author track record is a weak signal and it is a signal. A group that has published carefully for years is a…
-
Alcohol: what is documented and what is folklore Replied, post #115 · Practice › Interactions · 16 Jul 2026 · 2 likes Fine by me. I had wanted a stronger conclusion and there is not one available.
-
Journal club: SUSTAIN 6 and its retinopathy signal Replied, post #56 · Evidence › Journal club · 13 Jul 2026 · 0 likes Two claims get bundled together under SUSTAIN 6 and they need separating. The descriptive one — this is what was observed — is usually well supported. The causal one —…
-
What to bring: records that a clinician can actually use — a second dataset Replied, post #17 · Clinical › Prescriber conversations · 8 Jul 2026 · 2 likes Discussing off-label dosing: if you want to dose differently than the label specifies (slower titration, higher final dose), discussing that explicitly and…
-
Follow-up: Prior authorisation: what the criteria usually require Replied, post #60 · Access › Insurance & coverage · 7 Jul 2026 · 4 likes Everything in post #57 holds. The case it does not cover is the one I have. The claim about Prior authorisation upthread is stronger than its source supports. I have…
-
Comparing my trajectory with the trial curves, carefully — a second dataset Replied, post #71 · Outcomes › Progress reports · 6 Jul 2026 · 4 likes Nothing here is medical advice and a progress report is a description of what happened to one person under uncontrolled conditions. Two sources, same conclusion, and I…
-
[2026 update] Interpreting a result that disagrees with the supplier's certificate Replied, post #64 · Sourcing › Independent verification · 4 Jul 2026 · 0 likes Blind sampling: submitting without the laboratory or seller knowing the source removes the two easiest ways for a result to be shaped: selective submission and…
-
GIP receptor agonism and the argument about direction — does this still hold? Replied, post #6 · Pharmacology › Receptor biology · 3 Jul 2026 · 6 likes Everything in post #2 holds. The case it does not cover is the one I have. Cross-reactivity and selectivity: the compounds are not perfectly selective for their target…
-
Search filters: what is missing Replied, post #75 · Meta › Site feedback · 30 Jun 2026 · 6 likes Accessibility: screen readers, keyboard navigation, contrast, font size — if something is not accessible to you, report it. Accessibility matters.